A Drug Enforcement Administration (DEA) judge has denied a cannabis research company’s request to allow it to add a young medical marijuana patient and advocate as a witness in an upcoming hearing on the Biden administration’s proposal to reschedule the drug.
Cannabis Bioscience International Holdings (CBIH) had filed a motion to add Alexis Bortell as a witness late in the process, saying that it experienced challenges contacting her earlier. But in an order issued on Wednesday, DEA Administrative Law Judge (ALJ) John Mulrooney said the “purported, unspecified difficulties in contacting its new proposed witness” did not amount to “good cause” for the lat request.
“There was no indication in CBIH’s prehearing statement that it was endeavoring to locate an additional witness or evidence, and the only noticed witness for the organization is its director, the drafter of the Motion to Amend, who is representing his company as a non-lawyer,” the judge said.
The motion “exceeds the one-witness-per-Designated-Party limitations established in this case, without consolidation or an adequate demonstration of good cause for doing so,” the order said. “Additionally, the Motion to Amend presents insufficient credible good cause for late notice, and seeks to present testimony that is essentially anecdotal.”
Even
Read full article on Marijuana Moment
